APOC3 and atherosclerosis: Importantly, thrombocytopenia has been reported in FCS patients with volanesorsen treatment; however, this study showed that depleting ApoC3 by CRIPSR/Cas9 resulted in abnormal platelet indices without thrombocytopenia, indicating that genetically targeting ApoC3 could not significantly cause decreased platelet number; however, the abnormal platelet function due to ApoC3 deletion would be considered as another potential contributor to atherosclerosis in our study.